• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Suvorexant May Prevent Delirium in Hospitalized Patients

Suvorexant May Prevent Delirium in Hospitalized Patients

May 21, 2021
Alexander Thompson, MD, MBA, MPH
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Alexander Thompson, MD, MBA, MPH Dr. Thompson has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Hatta K et al, J Clin Psychiatry 2017;78(8):e970–e979; Hatta K et al, J Clin Psychiatry 2019;81(1):19m12865

Delirium is an acute confusional state that occurs frequently in older hospitalized patients, especially those with serious illness in the ICU. We try our best to prevent it because it is associated with worse medical outcomes, including mortality. Since one of the hallmarks of delirium is interrupted sleep, sedative-hypnotics are a natural treatment option. Unfortunately, benzodiazepines can worsen delirium. Non-benzodiazepine hypnotics such as ramelteon (a melatonin receptor agonist) and melatonin have shown promise at preventing delirium in small clinical trials. Recently, two trials examined whether a novel hypnotic, suvorexant (an orexin receptor antagonist), prevents delirium in patients at risk.

In the first study, 72 acute hospitalized patients, ages 65–89, were randomized to either suvorexant (15 mg given at 9 pm) or placebo for 3 days. The patients were followed for 7 days, starting the day after the drug was first given. Six placebo-receiving patients became delirious, while no suvorexant patients became delirious (17% vs 0%; p = 0.025). There was no difference in subjective or clinician-rated sleep parameters (such as total minutes of sleep) between the two groups.

The second study was a non-randomized “real-world” follow-up study examining delirium incidence in hospitalized patients given ramelteon (8 mg/day), suvorexant (15 mg/day), or both, compared to patients who chose to take neither. Those who took ramelteon and/or suvorexant developed delirium less frequently than those who took neither (63/401 = 16% vs 30/125 = 24% [RR 1.5]).

Researchers also studied patients who had been delirious the night before but were no longer confused the day the study started. Of this group, those who chose to take ramelteon and/or suvorexant also were less likely to develop delirium (133/333 = 40% vs 59/89 = 66% [RR 1.7]) and also showed sleep/wake cycle improvements at the end of the intervention.

CHPR’s Take
While suvorexant appears effective at preventing delirium, it’s unlikely to be a first-line agent in your hospitalized patients. Given its cost, it’s usually not on hospital formularies, and it can cause significant next-day sedation and even sleep paralysis and cataplexy, especially if used at higher doses (30–40 mg/day). For these reasons, if a sleeping agent is needed in your hospitalized patients, we recommend starting with ramelteon and only using suvorexant as a second- or third-line agent. Continue recommending common interventions to prevent delirium, including reorientation, uninterrupted sleep hours, hydration, avoidance of delirium-causing medications, and active treatment of underlying medical ­conditions.
Hospital Psychiatry
KEYWORDS delirium geriatric-psychiatry suvorexant
Alexander Thompson, MD, MBA, MPH

More from this author
www.thecarlatreport.com
Issue Date: May 21, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Capacity Assessments, CHPR, April/May/June 2021
Finally, Effective Treatments for Tardive Dyskinesia
Decisional Capacity
Capacity Assessment in Pregnant Patients
Suvorexant May Prevent Delirium in Hospitalized Patients
SSRIs and Intracerebral Hemorrhage Risk
Can Antidepressants Prolong Survival in Cancer Patients?
Hyperprolactinemia: Effective Treatment With Aripiprazole
Note From the Editor-in-Chief
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.